Gregory Oakes - 29 Feb 2024 Form 4 Insider Report for Landos Biopharma, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Gregory Oakes
Issuer symbol
N/A
Transactions as of
29 Feb 2024
Net transactions value
$0
Form type
4
Filing time
04 Mar 2024, 16:06:34 UTC
Previous filing
02 Mar 2023
Next filing
23 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Restricted Stock Unit Award $0 +54,454 $0.000000 54,454 29 Feb 2024 Common Stock 54,454 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the right to receive one share of Landos Biopharma, Inc., Inc. common stock.
F2 The Restricted Stock Unit ("RSU") shall vest as to 66 2/3% of the shares underlying the RSU on the second anniversary of the date of grant and shall vest as to 33 1/3% of the shares underlying the RSU on the third anniversary of the date of grant, subject to the Reporting Person's continuous service with the Issuer on each such date.